Evidence map›Paper›PMID 33247633›Full record

Observational studyCancer medicine2021

Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.

Hala T Borno, Tracy Kuo Lin, Anobel Y Odisho, Arpita Desai, Vadim Koshkin, Kalin Werner, Nichole Legaspi, Matthew Bucknor, Alexander Bell, Sylvia Zhang and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hala T BornoDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4357-9759
Tracy Kuo LinDepartment of Social and Behavioral Sciences, Institute for Health & Aging, University of California San Francisco, San Francisco, CA, USA.
Anobel Y OdishoDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0975-0812
Arpita DesaiDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Vadim KoshkinDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Kalin WernerDivision of Emergency Medicine, University of Cape Town, Cape Town, South Africa.
Nichole LegaspiDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Matthew BucknorDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Alexander BellSchool of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1684-1827
Sylvia ZhangDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular imaging with novel radiotracers is changing the treatment landscape in prostate cancer (PCa). Currently, standard of care includes either conventional and molecular imaging at time of biochemical recurrence (BCR). This study evaluated the determinants of and cost associated with utilization of molecular imaging for BCR PCa.

methodsThis is a retrospective observational cohort study among men with BCR PCa from June 2018 to May 2019. Multivariate logistic regression models were employed to analyze the primary outcome: receipt of molecular imaging (e.g. Fluciclovine PET and Prostate Specific Membrane Antigen PET) as part of diagnostic work-up for BCR PCa. Multivariate linear regression models were used to analyze the secondary outcome: overall healthcare cost within a 1-year time frame.

resultsThe study sample included 234 patients; 79.1% White, 2.1% Black, 8.5% Asian/Pacific Islander, and 10.3% Other. The majority were 55 years or older (97.9%) and publicly insured (74.8%). Analysis indicated a one-unit reduction in PSA is associated with 1.3 times higher likelihood of receiving molecular imaging (p < 0.01). Analysis found that privately insured patients were associated with approximately $500,000 more in hospital reimbursement (p < 0.01) as compared to the publicly insured. Additionally, a one-unit increase in PSA is associated with $6254 increase in hospital reimbursement or an increase in total payments by 2.1% (p < 0.05).

conclusionsHigher PSA was associated with lower likelihood for molecular imaging and higher cost in a one-year time frame. Higher cost was also associated with private insurance, but there was no clear relationship between insurance type and imaging type.

Indexed as

Molecular Diagnostic TechniquesPositron-Emission TomographyAgedAged, 80 and overAntigens, SurfaceGlutamate Carboxypeptidase IIHealth Care CostsHealthcare DisparitiesHumansInsurance, HealthKallikreinsMaleMiddle AgedPredictive Value of TestsPregnancyPrognosisAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIKallikreinsKLK3 protein, humanProstate-Specific Antigenbiochemical recurrencedisparitiesmedical oncologymolecular imagingprostate cancer

Identifiers

PMID33247633
PMCPMC7826487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.